The AGA has issued new clinical guidelines that outline when to use new irritable bowel syndrome (IBS) medications, when to rely on old drugs, and when to use over-the-counter medications to treat patients with IBS-C (constipation) or IBS-D (diarrhea). In this course, Dr. Zumach discusses the guidelines and helps you provide personalized drug therapy recommendations for your patients.

Upon successful completion of this application-based CPE course, pharmacists should be able to:
1. Review epidemiology, pathophysiology, symptoms, and diagnoses of irritable bowel syndrome (IBS) with diarrhea (IBS-D) and constipation (IBS-C)
2. Describe key features of the American Gastroenterological Association’s (AGA) clinical updates for management of IBS-D and IBS-C and chronic gastrointestinal pain in disorders of gut-brain interaction
3. Determine realistic goals of therapy in a patient with IBS
4. Develop pharmacologic and nonpharmacologic therapy recommendations for a patient with IBS based on practice guidelines and applicable primary literature

Gregory M. Zumach, PharmD, BCPS
Clinical Assistant Professor
Oregon State University College of Pharmacy

Dr. Zumach has no relevant financial relationships with ineligible companies to disclose. 

Course fee includes course, course materials, and CPE credit submission to CPE Monitor.
Course is non-refundable.
Initial Release Date: December 1, 2022
Planned Expiration Date: December 1, 2025

Copyright 2022, CEimpact. All Rights Reserved. Any reproduction of this course without express permission is strictly forbidden.